Background History SSRIs for VMS
|
|
- Amberly Foster
- 6 years ago
- Views:
Transcription
1 .pptx Non hormonal Pharmacologic Options: SSRIs/SNRIs/Gabapentin Susan D. Reed, MD, MPH Department of Obstetrics and Gynecology University of Washington, Seattle, WA Christopher Rasmussen, MD, InflaNATION Blog Background History SSRIs for VMS ective+serotonin+reuptake+inhibitors Anecdotal evidence of hot flash benefit in men and women with cancer Loprinzi, 199 Quella, 1999 First RCT Loprinzi, 2000 Loprinzi CL. J Clin Oncol 199;16: Quella S. J Urol 1999; 162: Loprinzi CL. Lancet 16 December 2000; 356: Disclosures MsFLASH Menopause strategies Finding Lasting Answers for Symptoms and Health. National Institute on Aging (NIA) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) The National Center for Complementary and Alternative Medicine (NCCAM) The Office of Research on Women's Health (ORWH) (U01 AG032699) Escitalopram, Venlafaxine Objective Explain the evidence supporting SSRIs, SNRIs and gabapentin for menopausal symptoms and be able to counsel patients on their efficacy and side effect profile Discuss relative safety and the probable physiologic action of these medications 1
2 .pptx Additional Questions SSRIs, SNRIs, Gabapentin Equally effective in women with and without breast cancer? What about interactions, cyp2d6, tamoxifen? How to dose? How do non-hormonal pharmaceuticals compare with hormonal therapies? - onset of action -efficacy - side effects - other benefits -price Menopausal Hot Flash Control Kappa Agonist GABA? Norepinephrine? Serotonin? Estrogen Progesterone? Clifton D, Oakley A, 2014 Additional Questions SSRIs, SNRIs, Gabapentin Equally effective in women with and without breast cancer? Yes (Bardia, 2009) Can paroxetine be used in women with breast cancer on tamoxifen? Controversial (Rae, 2012; Regan, 2012 ) Dosing? In general, doses < for depression How do nonhormonal pharmaceuticals compare with hormonal therapies? - onset of action: faster -efficacy: < standard dose estrogen formulations - side effects: some women do not tolerate - other benefits: pain, sleep, mood -price: similar Bardia A. Menopause 2009;16(3): Rae JM. J Natl Cancer Inst 2012;104: Regan M. J Natl Cancer Inst 2012;104: Efficacy, Cost, Side Effects SSRIs, SNRIs, Gabapentin part they dont tell you ssri discontinuation syndrome 2
3 .pptx ANNA BRCA1 carrier Refuses HT, sister has breast cancer Has mod HF, sleeping poorly, mild joint pain On tamoxifen for prevention On citalopram 20 mg for mood sheknows.com Her friend takes gabapentin and she wants to try this, but asks about efficacy, and in particular, benefit compared with estrogen and other nonhormonal therapies Randomized double blind placebo controlled trials: Nonhormonal R for VMS At least 1 wk baseline hot flash data (preferably 2-3 wk), >6 HF/d baseline No cross-over designs, non-depressed women 4 wk, preferably > week duration Provide data on frequency, severity Outcome - change from baseline compared with placebo Cyp2d6, SSRIs, Tamoxifen Cytochrome p450 inhibition GABA-nergic placebo controlled trials Paroxetine mesylate Paroxetine HCl Escitalopram Citalopram Venlafaxine Desvenlafaxine NO/LOW MODERATE HIGH Gabapentin IR: INCLUDE Guttuso, 2003; Pandya, 2005; Butt, 200; ECLUDE: Reddy, 2006 outcome not shown as HF frequency; Saadati, 2013 not blinded, no placebo response Gabapentin GR: INCLUDE Pinkerton, 2014 Pregabalin: INCLUDE Loprinzi, Co administration of paroxetine 10 mg/d with tamoxifen decreased plasma concentrations of endotoxifen by 64% (Stearns, 2003) CYP2D6 genotype does not appear to predict clinical benefit with adjuvant tamoxifen therapy in postmenopausal breast cancer patients, in conjunction with or without SSRIs (Rae, 2012) GABAPENTIN: Guttuso JL. Obstet Gynecol 2003;101(2):337. Pandya KJ. Lancet 2005;366(94):1.Butt DA. Menopause 200;15(2):310. Pinkerton JV. Menopause 2014;21(6): PREGABALIN: Loprinzi CL. J Clin Oncol 2010; 2(4):
4 .pptx Gabapentin IR 900 mg/d (300 tid) Pregabalin 150 mg/d (75 bid) VMS Frequency VMS Severity Guttuso JL. Obstet Gynecol 2003;101(2):337. Loprinzi CL. J Clin Oncol 2010; 2(4): 641. Gabapentin GR 100 mg/d (600 am, 1200 pm) mg pm Gabalin, Pregabalin Benefit: 1 2 HF/d N Duration (weeks) Frequency from BL Active vs PL HF/d BL Overall HF/d Severity VMS Frequency Gabapentin IR 300, 900 mg 347/ / vs vs vs ~ *Gabapentin GR 600, 1200, 100 mg Pregabalin 150, 300 mg 593/ vs >7 ** ~ / vs 2.9 >6 ~ VMS Severity Pinkerton JV. Menopause 2014;21(6): *Industry supported, ** Moderate to severe HF GABAPENTIN IR:. Guttuso JL. Obstet Gynecol 2003;101(2):337. Pandya KJ. Lancet 2005;366(94):1. Butt DA. Menopause 200;15(2):310. GABAPENTIN GR: Pinkerton JV. Menopause 2014;21(6): PREGABALIN: Loprinzi CL. J Clin Oncol 2010;2:641. 4
5 .pptx Approximate Price per month supply Price per month Paroxetine mesylate $165 Paroxetine HCl $25 Escitalopram $49 Citalopram $34 Venlafaxine $40 Desvenlafaxine $10 Gabapentin IR $29 Gabapentin GR $443 Pregabalin $336 accessed Sept 1, 2014 ANNA Chooses Gabapentin IR because she is worried about health care costs You prescribe 300 mg nightly for at least 3 nights and ask her to titrate to 900 mg nightly as tolerated, then if still bothered in the day take 300 mg every morning She returns in one month, sleeping better and happy with treatment, but stopped the morning dose due to drowsiness sheknows.com Oral Estradiol Comparisons SSRI/SNRI,Gabapentin faster onset than E2 Similar efficacy to low dose oral E2? Notelovitz M. Obstet Gynecol 2000; ;95(5):726. Reddy S. Obstetrics & Gynecology 2006; 10(1):41. Joffe H. JAMA Int Med, 2014;174(7):105.. ESTRADIOL c c VENLAFAINE GABAPENTIN Benefits/Side effects Tailor therapy to your patient Benefits Side effects Paroxetine Nausea, fatigue, dizzy Escitalopram Pain Nausea, sweating, dizzy Citalopram Drowsy, sweating, dizzy, sexual function Venlafaxine Pain Nausea, headache, BP, jittery Desvenlafaxine Nausea, vomiting Gabapentin IR Pain Dizzy, unsteady, drowsy Gabapentin GR Pain Dizzy, headache, drowsy Pregabalin Pain Dizzy, cognition, drowsy, blurry vision, weight gain Potential for: nausea, insomnia, dizziness, headache, dry mouth, diarrhea, bloating, constipation, insomnia, sexual dysfunction 5
6 .pptx Benefits/Side effects Tailor therapy to your patient Majority of side effects are self limiting and resolve in first 2-4 weeks Higher rate of side effects in depressed populations Side effects vary from woman to woman Close follow up and encouragement are critical for ongoing adherence A small % of women do not tolerate Placebo controlled trials with VMS benefit Paroxetine*: INCLUDE Simon, 2013; Stearns, 2003; ECLUDE Stearns, 2005, x-over design; Soares, 200, small study low baseline VMS Escitalopram: INCLUDE Freeman, 2011 Citalopram: INCLUDE Barton, 2010; ECLUDE Suvanto-Luukkonen, 2005, lacking baseline measure VMS Venlafaxine: INCLUDE Joffe, 2014; Loprinzi, 2000; ECLUDE Carpenter, 2007, x-over design; Loprinzi, 2003 < 6 HF/d, Evans, 2005, lack baseline VMS ) Desvenlafaxine*: INCLUDE Speroff, 200; Archer, 2009; Archer 2009; Pinkerton, 2013 * Industry sponsored studies MARTHA Placebo controlled trials unknown VMS benefit Having moderate hot flashes Low mood Best friend with ovarian cancer, does not want HT Interested in SSRI/SNRI, but is worried about diminished sexual function more.com Sertraline (INCLUDE: Grady, 2007; ECLUDE: Kimmick, 2006; Gordon, 2006, cross over designs) Grady: 7-day baseline HF, relatively small n=100,.9 BL HF 3.5 HF both groups at 6 wk Group differences: Placebo older, caucasian, high SES; Sertraline younger, AA, low SES Grady D. Obstet Gynecol 2007;109:23 30 Kimmick GG. Breast J 2006;12: Gordon PR. Menopause 2006;13(4):
7 .pptx Placebo controlled trials unknown VMS benefit Paroxetine CR Hot Flash Composite Score, 12.5 mg/d Fluoxetine: No trials fit my inclusion criteria ECLUDE Suvanto-Luukkonen, 2005, lacking baseline measure VMS; Loprinzi, 2002, x-over Suvanto Luukkonen E. Menopause 2005;12:1 26. Loprinzi CL. J Clin Oncol 2002;20(6):157. Error bars indicate SE. Compared with placebo, the mean reduction in the hot flash composite score for those taking 25.0 mg/d of paroxetine CR was statistically significant (P<.05 in weeks1, 2, 3, and 4; P<.001 in weeks 5 and 6); for those taking 12.5 mg/d of paroxetine CR, the mean reduction in the hot flashcomposite score was statistically significant in weeks 1, 3, and 6 (P<.05) and in week 5 (P<.001). Stearns V. JAMA. 2003;29(21): doi: /jama No placebo controlled double-blind trials Escitalopram 10 mg/d Duloxetine Fluvoxamine Quetiapine R Hot Flash per Day Intervention Post Intervention Placebo Escitalopram Week Escitalopram vs placebo (weeks 4, ) P=0.001 Freeman E, JAMA 2011;305(3):267. 7
8 .pptx Citalopram 10 mg/d Desvenlafaxine 100 mg/d c Speroff L. Obstet Gynecol 200; 111(1):77. Archer D. AJOG 2009;200:23. Barton D L et al. JCO 2010;2: Venlafaxine 75 mg/d Loprinzi CL. Lancet 2000:9247: Joffe H. JAMA Intern Med 2014 ;174(7):105. SSRI, SNRIs Benefit: 1 3 HF/d N Duration Frequency HF/d HF/dHF/dVMS **Paroxetine 7.5, 12.5CR, 25CR mg Escitalopram 10, 20 mg Citalopram 10, 20, 30 mg Venlafaxine 37.5, 75, 150 mg **Desvenlafaxine 50, 100, 150, 200 mg 160/ /614* (weeks) 6 12 from BL Active vs PL 3.3 vs vs 5.3 BL * Overall HF/d ~0.9 ~ 1.1* Severity 200/ vs ~ vs 1.4 ~ /620* 436/452* 541/567* 319/365* (n=36) vs vs vs vs vs vs * 10.* 10.6* 11.* + ~ ~ * + * Moderate Severe HF, ** Industry sponsored PAROETINE: Stearns V. JAMA. 2003;29 (21): ; Simon JA. Menopause ;20 (10):1027. ESCITALOPRAM: Freeman E. JAMA 2011;305(3):267. CITALOPRAM: Barton D. J Clin Oncol 2010;2(20):327. VENLAFAINE: Loprinzi CL, Lancet 2000;356: Joffe H. JAMA Internal Med 2014;174(7):105. DESVENLAFAINE: Speroff L. Obstet Gynecol 200;111:77; Archer DF. Am J Obstet Gynecol 2009; 200:17; Archer DF..Am J Obstet Gynecol 2009; 200:23. Pinkerton J. Menopause 2013;20(1):3 46.
9 .pptx Approximate Price per month supply Price per month Paroxetine mesylate $165 Paroxetine HCl $25 Escitalopram $49 Citalopram $34 Venlafaxine $40 Desvenlafaxine $10 Gabapentin IR $29 Gabapentin GR $443 Pregabalin $336 accessed Sept 1, 2014 Benefits/Side effects Tailor therapy to your patient Benefits Side effects Paroxetine Nausea, fatigue, dizzy Escitalopram Pain Nausea, sweating, dizzy Citalopram Drowsy, sweating, dizzy, sexual function Venlafaxine Pain Nausea, headache, BP, jittery Desvenlafaxine Nausea, vomiting Gabapentin IR Pain Dizzy, unsteady, drowsy Gabapentin GR Pain Dizzy, headache, drowsy Pregabalin Pain Dizzy, cognition, drowsy, blurry vision, weight gain All have potential for: nausea, insomnia, dizziness, headache, dry mouth, diarrhea, bloating, constipation, insomnia, sexual dysfunction MARTHA R paroxetine mesylate 7.5 mg because she wants an FDA approved product and wants the lowest dose possible She returns in wks much improved, but thinks she may be a little drowsy during the day. She was told by her girl friend that she will not be able to orgasm. How do you counsel her? more.com Placebo Controlled Trials Quality Of Life Sleep Sexual Quality of Life Function Paroxetine ASE Escitalopram FSFI Menqol Citalopram orgasm HFRDIS Venlafaxine FSFI Menqol Desvenlafaxine Greene Climacteric Gabapentin * Menqol PAROETINE: Pinkerton JV. Menopause August, 2014; Portman DJ. Menopause February, 2014; Stearns V. JAMA. 2003;29 (21): ESCITALOPRAM: LaCroix AZ. Maturitas 2012 Dec;73(4):361-. Ensrud KE. Menopause. 2012;19():4-55. Reed SD. Obstet Gynecol. 2012;119(3): CITALOPRAM: Barton D. J Clin Oncol 2010;2(20):327. VENLAFAINE: Reed SD. Obstet Gynecol 2014;124(2 ):233. Ensrud KE Sleep, 2014D. Caan B, Menopause, 2014 DESVENLAFAINE: Speroff L. Obstet Gynecol 200;111:77. GABAPENTIN: Yurchesen ME. J Womens Health 2009 Sep;1(9): *Butt DA. Menopause 200;15(2):310. 9
10 .pptx Conclusions Paroxetine, Escitalopram, Citalopram, Venlafaxine, Desvenlafaxine, Gabapentin and Pregabalin are effective for decreasing HF and in many cases, improve QOL for menopausal women The effect is modest, 50-60% decrease (~1-3 HF/d) SSRIs, SNRIs and gabapentin are effective in women with and without breast cancer Their effect may be similar to low dose oral estrogen (0.5 mg estradiol) Side effects in some women will preclude their use, though in general these R are relatively well tolerated at low doses Costs vary considerably Tailor therapy consider sleep, pain, sexual function, QOL VMS studies predominantly in white women, with exception of Escitalopram MsFLASH Collaborators Ellen Freeman, PhD Hadine Joffe, MD Lee Cohen, MD Janet Carpenter, RN, PhD Katherine Guthrie, PhD Joe Larson, MS Questions SSRIs, SNRIs and Gabapentin for Menopause 10
Non hormonal medical treatment of vasomotor symptoms
Non hormonal medical treatment of vasomotor symptoms Caroline Antoine Menopause Clinic Department of Gynaecology and Obstetrics CHU Saint-Pierre Belgian Menopause Society Symposium November 14, 2015 No
More informationLiving with an Induced Menopause
Living with an Induced Menopause Dr Jenifer Sassarini Clinical Lecturer Obstetrics and Gynaecology University of Glasgow 2 February 2017 70% of women in UK living with breast cancer have hot flushes 1/3
More informationTreatment of Mood Disorders in Midlife Women
Treatment of Mood Disorders in Women KAY ROUSSOS-ROSS, MD UNIVERSITY OF FLORIDA DEPARTMENTS OF OBGYN AND PSYCHIATRY Disclosures I HAVE NO DISCLOSURES Objectives UNDERSTAND INCIDENCE OF MOOD DISORDERS IN
More informationVenlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients a double-blind, randomized study
Annals of Oncology 18: 689 693, 2007 doi:10.1093/annonc/mdl478 Published online 17 January 2007 is superior to as treatment of hot flashes in breast cancer patients a double-blind, randomized study S.
More informationPrimary Care of the Breast Cancer Survivor. Case Presentation. Case Presentation (cont) Case Presentation (cont) Breast Cancer
Primary Care of the Breast Cancer Survivor Janet P. Pregler, MD Professor of Clinical Medicine Director, Iris Cantor UCLA Women s Health Center Case Presentation B.C. is a 58 year-old African American
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationSleep in the Menopause Transition
Sleep in the Menopause Transition Hadine Joffe, MD, MSc Director, Women s Hormone & Aging Research Program www.brighamwharp.org Associate Professor, Harvard Medical School Vice Chair for Research & Director
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationPharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007
Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual
More informationManagement of Menopausal Symptoms in Patients with Breast Cancer. Mike Dixon Edinburgh Breast Unit
Management of Menopausal Symptoms in Patients with Breast Cancer Mike Dixon Edinburgh Breast Unit Menopausal symptoms have a major impact on Quality of Life Variety of Symptoms associated with the Menopause
More informationManagement of Perimenopausal symptoms
Management of Perimenopausal symptoms Serge Rozenberg CHU St Pierre Université libre de Bruxelles Belgium serge_rozenberg@stpierre-bru.be serge.rozenberg@skynet.be Conflict of interest & Disclosure Conflicts
More informationCase Presentation. Learning Objectives. Case Presentation. Case Presentation
Learning Objectives To apply up to date information about the natural history of menopause to improve the care of individual women To counsel women about the risks and benefits of systemic hormone therapy
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationMENOPAUSAL HORMONE THERAPY 2016
MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationHormone therapy for menopausal vasomotor symptoms
Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert
More informationAssessment and Treatment of Depression in Menopause
Disclosures Assessment and Treatment of Depression in Menopause Susan G. Kornstein, MD Professor of Psychiatry and Obstetrics-Gynecology Executive Director, Institute for Women s Health Virginia Commonwealth
More informationEffect of escitalopram on hot flash interference: a randomized, controlled trial
Effect of escitalopram on hot flash interference: a randomized, controlled trial Janet S. Carpenter, Ph.D., R.N., a Katherine A. Guthrie, Ph.D., b Joseph C. Larson, M.S., b Ellen W. Freeman, Ph.D., c Hadine
More informationIs Desvenlafaxine Effective for Reducing Hot Flashes In Postmenopausal Females?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Desvenlafaxine Effective for Reducing
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationManagement of Menopausal Symptoms
Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of
More informationConflicts-donations to Mayo. Pfizer -pregabalin to prevent paclitaxel-induced neuropathy Competitive Technologies- donated Scrambler machines
Conflicts-donations to Mayo Pfizer -pregabalin to prevent paclitaxel-induced neuropathy Competitive Technologies- donated Scrambler machines Symptom Management of Therapy-Related Toxicities Charles L Loprinzi
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationCitation for published version (APA): Buijs, C. (2008). Long-term side effects of adjuvant breast cancer treatment s.n.
University of Groningen Long-term side effects of adjuvant breast cancer treatment Buijs, Ciska IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationBefore you prescribe
Initiating hormone replacement therapy (HRT) / menopausal hormone therapy (MHT) Dr Sonia Davison Jean Hailes Consultant Endocrinologist Before you prescribe Ensure there are no contraindications to HRT/MHT
More informationOverview: Identifying Candidates and Tailoring Treatment. Disclosures 10/6/2014. Vasomotor Symptoms. VMS in Postmenopausal Women
Overview: Identifying Candidates and Tailoring Treatment Risa Kagan, MD, FACOG, CCD, NCMP Clinical Professor, Department of Ob-Gyn, UCSF East Bay Physicians Medical Group Sutter Foundation, Berkeley, CA
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationGabapentin to treat hot flashes
P ford residence southampton, ny Gabapentin to treat hot flashes 6-10-2010 An extendedrelease version of the seizure and pain drug gabapentin may be one step closer to becoming the first approved nonhormonal
More informationJoe Barton, MA, LPC, NCC National Certified Counselor Faculty Associate, TTUHSC Amarillo Family Medicine Department Barton Behavioral Health
Joe Barton, MA, LPC, NCC National Certified Counselor Faculty Associate, TTUHSC Amarillo Family Medicine Department Barton Behavioral Health Solutions, PLLC www.bartoncbt.com Academic and Pop-Culture
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationEstradiol versus venlafaxine for vasomotor symptoms
Released June 26, 2014 This e-newsletter presents reviews of important, recently published scientific articles selected by The North American Menopause Society (NAMS), the leading nonprofit scientific
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationUsing an FSDS-R Item to Screen for Sexually Related
Using an FSDS-R Item to Screen for Sexually Related Distress: A MsFLASH Analysis The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
More informationTreatment of Anxiety (without benzos)
Treatment of Anxiety (without benzos) Alison C. Lynch MD MS Clinical Professor Departments of Psychiatry and Family Medicine University of Iowa Health Care None Disclosures Overview/objectives Review common
More information9/25/18. REED Vulva LA Tak due Vulvar Talk LA January 2016.pptx LEARNING OBJECTIVES DISCLOSURES KNDY NEURONS SECRETE NEUROPEPTIDES
UW MEDICINE NAMS 2018 RECENT ADVANCES IN THE TREATMENT OF VASOMOTOR SYMPTOMS May Be the New Sweet Spot Istockphoto.com Susan D Reed, MD, MPH Professor and Vice Chair Department of Obstetrics and Gynecology
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationHot flushes in breast cancer patients
Critical Reviews in Oncology/Hematology 57 (2006) 63 77 Hot flushes in breast cancer patients Constantijne H. Mom a, Ciska Buijs a, Pax H.B. Willemse a, Marian J.E. Mourits b, Elisabeth G.E. de Vries a,
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationConflicts-donations to Mayo. Pfizer -pregabalin to prevent paclitaxel-induced neuropathy Competitive Technologies- donated Scrambler machines
Conflicts-donations to Mayo Pfizer -pregabalin to prevent paclitaxel-induced neuropathy Competitive Technologies- donated Scrambler machines Symptom Management of Therapy-Related Toxicities Charles L Loprinzi
More informationIssues in Cancer Survivorship. Larissa A. Korde, MD, MPH June 26, 2010
Issues in Cancer Survivorship Larissa A. Korde, MD, MPH June 26, 2010 Estimated US Cancer Cases in Women: 2006-2008 CA Cancer J Clin 2006; 56:106-130; CA Cancer J Clin 2008;58:71 96. Relative Survival*
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationpii: zsx190 http://dx.doi.org/10.1093/sleep/zsx190 ORIGINAL ARTICLE Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes:
More informationSexual Function in Nondepressed Women Using Escitalopram for Vasomotor Symptoms A Randomized Controlled Trial
Sexual Function in Nondepressed Women Using Escitalopram for Vasomotor Symptoms A Randomized Controlled Trial Susan D. Reed, MD, MPH, Katherine A. Guthrie, PhD, Hadine Joffe, MD, MSc, Jan L. Shifren, MD,
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationNon-hormonal interventions for hot flushes in women with a history of breast cancer (Review)
Non-hormonal interventions for hot flushes in women with a history of breast cancer (Review) Rada G, Capurro D, Pantoja T, Corbalán J, Moreno G, Letelier LM, Vera C This is a reprint of a Cochrane review,
More informationTreatment of Vasomotor Symptoms in a Transgender Male After Hysterectomy. Isabel Casimiro, MD PhD Endocrinology Fellow
Treatment of Vasomotor Symptoms in a Transgender Male After Hysterectomy Isabel Casimiro, MD PhD Endocrinology Fellow Disclosure Information I have the following financial relationships to disclose: Consultant
More informationClinicians strive to individualize menopausal therapies.
Original Research Sexual Function in Women on Estradiol or Venlafaxine for Hot Flushes A Randomized Controlled Trial Susan D. Reed, MD, MPH, Caroline M. Mitchell, MD, MPH, Hadine Joffe, MD, MSc, Lee Cohen,
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationSelective Serotonin Reuptake Inhibitor (SSRI) Step Therapy Program
Selective Serotonin Reuptake Inhibitor (SSRI) Step Therapy Program Policy Number: 5.01.587 Last Review: 7/2018 Origination: 7/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationBreast Cancer Survivorship. Michelle Melisko MD Assistant Clinical Professor UCSF Breast Care Center
Breast Cancer Survivorship Michelle Melisko MD Assistant Clinical Professor UCSF Breast Care Center Survivors Who are they? An estimated 210,000 women were diagnosed with breast cancer in the year 2007
More informationNeurontin for menopause symptoms
Neurontin for menopause symptoms The Borg System is 100 % Neurontin for menopause symptoms "I have a herniated disc in my back and it's protruding in my spine on my nerve. I was just prescribed Neurontin
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationA Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
REVIEW ARTICLE Drug Saf 2011; 34 (9): 709-731 0114-5916/11/0009-0709/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationPresenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy
Depression, Anxiety, PTSD: A Focus on Pharmacotherapy Robert L Page II, Pharm.D., MSPH, FHFSA, FCCP, FAHA Professor of Clinical Pharmacy Clinical Specialist, Division of Cardiology University of Colorado
More informationPrimary Care Psychopharmacology for Anxiety Disorders. Holly Ellison, RN, MSN, PMHNP-BC Board Certified Psychiatric Mental Health Nurse Practitioner
Primary Care Psychopharmacology for Anxiety Disorders Holly Ellison, RN, MSN, PMHNP-BC Board Certified Psychiatric Mental Health Nurse Practitioner Prevalence of Any Anxiety Disorder Among U.S. Adults
More informationGary Elkins, PhD., ABPP
Gary Elkins, PhD., ABPP *What are Hot Flashes? *Hormone Replacement Therapy *Alternate Treatment Options *Clinical Hypnosis? *Methods *Preliminary Results *Conclusions & Future Directions *Over 66% of
More informationHot flushes (HF) are one of the most prominent
ORIGINAL ARTICLE Mirtazapine for the Treatment of Hot Flushes in Breast Cancer Survivors: A Prospective Pilot Trial Nicoletta Biglia, MD, PhD, Franziska Kubatzki, MD, Paola Sgandurra, MD, Riccardo Ponzone,
More informationEffects of Transdermal Estradiol in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial
Effects of Transdermal Estradiol in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial Jennifer L. Gordon 1,2, David R. Rubinow 1, Tory A. Eisenlohr-Moul 1,
More informationThe Good, The Bad, and The Ugly of Hormonal Therapy, Trastuzumab and Docetaxel
The Good, The Bad, and The Ugly of Hormonal Therapy, Trastuzumab and Docetaxel Diane Johnson Pharmacist, CCMB June 6 th, 2015 Presenter Disclosure Speaker: Diane Johnson Relationships with commercial interests:
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationEffective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: 2.04.38 Cytochrome P450 Genotype-Guided Treatment Strategy Genotype-Guided Tamoxifen Treatment Description Tamoxifen is prescribed
More informationPain CONCERN. Medicines for long-term pain. Antidepressants
Pain CONCERN Medicines for long-term pain Antidepressants Many people living with long-term pain (also known as chronic or persistent pain) are worried about using medicines like antidepressants. They
More informationThe presentations at NAMS reference Brisdelle as LDMP (low-dose mesylate salt of paroxetine), as it was referred to in clinical development.
Data on Brisdelle (Paroxetine) Capsules, the First and Only FDA-Approved Non- Hormonal Therapy for Moderate to Severe Vasomotor Symptoms Associated with Menopause, to be Presented at the 2013 Annual Meeting
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for granisetron
More informationFinancial Disclosures
Common Cases and Conundrums in Menopause care Dr. Kerstin Gustafson, MD, FRCSC Financial Disclosures Dr. Kerstin Gustafson, MD, FRCSC, NCMP Speaker fees: Amgen Bayer Merck Novartis Novo-Nordisk Warner-Chilcott
More informationEvaluation & Management of PowerPoint Cover Title. the High Risk Population. High Risk Clinic
Evaluation & Management of PowerPoint Cover Title the High Risk Population High Risk Clinic Subtitle Joanna Would Springman, Go Here PA-C Assessment Genetics Known genetic mutation Family history with
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other BUPROPION HCL WELLBUTRIN, 01653 WELLBUTRIN SR, WELLBUTRIN XL BUPROPION HBR APLENZIN 17050 16996 26198 CITALOPRAM CELEXA 10321 GPID 16344 HYDROBROMIDE DESVENLAFAXINE
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationFlashpoint: Regulating Your Body s Temperature. Presented by: Shari M. Lawson, MD MBA Date Presented: November 1,
Flashpoint: Regulating Your Body s Temperature Presented by: Shari M. Lawson, MD MBA Date Presented: November 1, 2014 1 Disclosures None 2 Objectives Today s discussion will cover How body temperature
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationUpdate on Menopause: What s New?
Karen Carlson, MD Current Clinical Issues in Primary Care 1 Update on Mepause: What s New? Karen Carlson, M.D. Massachusetts General Hospital Harvard Medical School Our agenda: Update on new data from
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationFirst and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Hot Flashes Now Available by Prescription in U.S.
First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Hot Flashes Now Available by Prescription in U.S. Pharmacies The availability of Brisdelle (Paroxetine) capsules offers the millions
More informationANTI-DEPRESSANT MEDICATIONS
ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change
More informationVenlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including:
Medication Guide VENLAFAXINE XR (venlafaxine hydrochloride) (Extended-Release Capsules) Read the Medication Guide that comes with venlafaxine hydrochloride extended-release before you start taking it and
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationPart 2: Pain and Symptom Management Depression
Guidelines & Protocols Advisory Committee Part 2: Pain and Symptom Management Depression Effective Date: February 22, 2017 Key Recommendations Before diagnosing and treating major depressive disorder,
More informationNoven Enters Co-Promotion Agreement with Shionogi for Brisdelle (Paroxetine) Capsules MIAMI and NEW YORK, January 13, 2014
Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle (Paroxetine) Capsules Co-Promotion to Extend Physician Awareness of the First and Only FDA-Approved, Non-Hormonal Treatment for Moderate
More informationOBSTETRICS & GYNECOLOGY
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Female Sexual Arousal
More informationEfficacy and Safety of Acupuncture for the Hot Flashes in Breast Cancer Patients Taking Adjuvant Tamoxifen : A Multicenter Study in Korean Women
Efficacy and Safety of Acupuncture for the Hot Flashes in Breast Cancer Patients Taking Adjuvant Tamoxifen : A Multicenter Study in Korean Women Daegu Catholic University Medical Center Department of Endocrine
More informationfor a safe and effective nonhormonal
Research www.ajog.org REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationPresentation Goals 4/14/2015. Pharmacology for Urinary Incontinence in Women. Medications Review anti muscarinic medications Focus on newer meds
Presentation Goals Pharmacology for Urinary Incontinence in Women Medications Review anti muscarinic medications Focus on newer meds Introduce beta adrenergic medications Current Concepts in Drug Therapy
More informationSpecial Issues in Menopause and Major Depressive Disorder
September 11, 2013 By Barbara L. Parry, MD [1] A risk to benefit ratio of treatment must be established to determine the optimal treatment for perimenopausal depression. Untreated depression during the
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More information5 (Mullan F. N Engl J Med 313(4):270-3)
Cancer Survivorship and the Role of Pharmacy Katerine Dumais, PharmD, MPH PGY-1 Pharmacy Practice Resident Memorial Regional Hospital www.fshp.org Objectives Pharmacists: Describe the definition of cancer
More informationPharmacological treatment of anxiety disorders where is
Pharmacological treatment of anxiety disorders where is the room for improvement? David S Baldwin, Professor of Psychiatry BAP Masterclass, 15 th April 2011 dsb1@soton.ac.uk Declaration of interests (last
More information